Cofrav indications
Cofrav hydrochloride SYRUP indicated for cough associated with wheeziness (bronchospasm) and tenacious phlegm (sputum).
Uses of Cofrav in details
Cofrav is used to treat breathing difficulties caused by excessive mucus secretions in the air passages associated with respiratory tract infections.
Cofrav description
Each tablet also contains lactose, maize or potato starch, gelatine and magnesium stearate as excipients.
The oral/inhalation solution also contains tartaric acid and methyl parahydroxybenzoate as excipients.
The syrup also contains tartaric acid, benzoic acid, sodium carboxymethylcellulose, glycerol, sorbitol solution, pharma flavor and ethanol as excipients.
Each capsule also contains lactose, cornstarch and magnesium stearate as excipients.
Cofrav HCl is N-cyclohexyl-N-methyl-(2-amino-3,5-dibromobenzyl)amine hydrochloride.
Cofrav dosage
Unless otherwise prescribed, the following doses are recommended:
Tablet: Adults and Children >12 years: 8 mg (1 tab) thrice daily; 6-12 years: 4 mg (½ tab) thrice daily; 2-6 years: 4 mg (½ tab) twice daily.
Oral Solution:
Adults and Children >12 years: 4 mL thrice daily; 6-12 years: 2 mL thrice daily; 2-6 years: 20 drops thrice daily; <2 years: 10 drops thrice daily.Inhalation Solution (with aerosol apparatus): It is generally recommended to warm inhalation solution to body temperature before inhalation. Patients with bronchial asthma may be advised to commencing inhalation after they have taken their regular bronchospasmolytic therapy.
Adults: 4 mL. Children >12 years: 2 mL; 6-12 years: 1 mL; 2-6 years: 10 drops; <2 years: 5 drops. All doses to be taken twice daily.
The solution may be diluted 1:1 in physiological saline solution. In order to avoid precipitation, the solution should be inhaled immediately after mixing. The combined administration of inhalation and oral application intensifies the effect, and is especially suited for the commencement of treatment in cases where the full effect is to be reached quickly.
Syrup: Adults and Children >12 years: 5 ml (1 tsp) thrice daily.
At commencement of treatment, it may be necessary to increase the total daily dose up to 48 mg in adults.
The syrup is sugar-free and therefore suitable for diabetics and small children.
Ampoule: Severe cases, before and after surgical intervention: 1 amp SC, IM or IV (duration of injection: 2-3 min) 2-3 times daily.
Capsule: Adults: 1 cap 3 times daily.
It is recommended for the initial phase of treatment usually lasting not more than a week.
Patients being treated with Cofrav should be notified of an expected increase in the flow of secretions.
Cofrav interactions
A reduction in dose of cardiac glycosides (e.g. digitalis) and quinidine might become necessary in patients suffering from congestive cardiac failure because of the positive inotropic effect of orciprenaline sulphate.
Cofrav hydrochloride SYRUP should not be administered concomitantly with beta-blocking agents, due to orciprenaline’s reversal of anti-hypertensive action.
The concomitant use of other sympathomimetic agents should be carefully controlled to avoid potentiation of effects.
Cofrav side effects
Cofrav’s pharmacological action may lead to gastric irritation. A transient rise in serum aminotransferase values have been reported due to Cofrav.
Orciprenaline sulphate, as a sympathomimetic agent, may precipitate a wide range of adverse effects. Side-effects include fear; anxiety, restlessness, tremor, insomnia, confusion, irritability, weakness and psychotic states. Appetite may be reduced and nausea and vomiting may occur. A rise in blood pressure which may produce cerebral haemorrhage and pulmonary oedema, tachycardia and cardiac arrhythmias, anginal pain, palpitations, and cardiac arrest. Hypotension with dizziness and fainting and flushing may occur. Other effects that may occur include difficulty in micturition and urinary retention; dyspnoea; weakness; headache; disturbances of glucose metabolism; sweating and hypersalivation. Muscle cramps or twitching or unpleasant taste may occur.
Cofrav contraindications
Cofrav hydrochloride SYRUP is contra-indicated in patients with known hypersensitivity to sympathomimetic amines or any of the other ingredients; hypertrophic obstructive cardiomyopathy; and tachyarrhythmia.
Sympathomimetics, such as orciprenaline sulphate, may interact with monoamine oxidase inhibitors (MAOI), and therefore Cofrav hydrochloride SYRUP should not be given to patients receiving such treatment or within 14 days of MAOI treatment termination.
Safety in pregnancy and lactation has not been established.
Active ingredient matches for Cofrav:
| Unit description / dosage (Manufacturer) | Price, USD |
| Cofrav 100 ml Syrup | $ 0.03 |
List of Cofrav substitutes (brand and generic names): | |
| Cofq-X (India) | |
| COFQ-X oral liqd 100ml (Cipla) | $ 0.36 |
| Cofree Tablet | |
| Cofree Tablet (Stadia Biotech) | $ 0.04 |
| Coftex-BT (India) | |
| Coftex-BT Bromhexine hydrochloride 8 mg, Terbutaline sulphate 2.5 mg, Menthol 5 mg, Guaiphenesin 100mg. SYR / 100ml (Santiago) | |
| 100ml (Santiago) | |
| COFTEX-BT syr 100ml (Santiago) | $ 0.66 |
| Cohexine (Thailand) | |
| Cohexine 8 mg x 50 x 10's (Community Pharm PCL) | |
| Cohexine 4 mg/5 mL x 60 mL (Community Pharm PCL) | |
| Cohexine syr 4 mg/5 mL 60 mL x 1's (Community Pharm PCL) | |
| Cohexine tab 8 mg 50 x 10's (Community Pharm PCL) | |
| Cold-Relieve Syr (India) | |
| Cold-Relieve Syr Phenylephrine hydrochloride2.5 mg, Chlorpheniraminemaleate 1.25 mg, Bromhexinehydrochloride 4 mg. SYR / 60ml (Medico HC) | $ 0.34 |
| 60ml (Medico HC) | $ 0.34 |
| COLD-RELIEVE SYR syr 60ml (Medico HC) | $ 0.34 |
| Copod B | |
| Copod B 100 ml Syrup (Mepfarma (Alna Biotech)) | $ 0.02 |
| Copod-B (India) | |
| Copod-B Bromhexine hydrochloride 2 mg, Terbutaline sulphate 1.25 mg, Guaiphenesin 50 mg. SYR / 100ml (Mepfarma) | $ 0.49 |
| 100ml (Mepfarma) | $ 0.49 |
| COPOD-B syr 100ml (Mepfarma) | $ 0.52 |
| Corivin (India) | |
| Corivin 60 ml Syrup (Olcare Laboratories) | $ 0.02 |
| CORIVIN 0.1% W/V NASAL DROPS 1 packet / 10 ML nasal drops each (Olcare Laboratories) | $ 0.38 |
| CORIVIN PEAD DROPS 1 packet / 10 ML drop each (Olcare Laboratories) | $ 0.34 |
| CORIVIN TABLET 1 strip / 10 tablets each (Olcare Laboratories) | $ 0.26 |
| CORIVIN nasal drops 0.1 % w/v x 10ml (Olcare Laboratories) | $ 0.42 |
| Corivin 0.1% w/v Nasal Drops (Olcare Laboratories) | $ 0.38 |
| Corivin NA Nasal Drops (Olcare Laboratories) | $ 0.34 |
| Corized E | |
| Corized E 100 ml Expectorant (Wander Ltd) | $ 0.01 |
| Cos P | |
| Cos P 100 ml Syrup (Biosync Pharmaceuticals Pvt Ltd) | $ 0.03 |
| Cos-P (India) | |
| Cos-P Terbutaline sulphate 2.5 mg, Bromhexine hydrochloride 8 mg, Guaiphenesin 100 mg, Menthol 2mg. SYR / 100ml (Biosync Pharma) | $ 0.54 |
| 100ml (Biosync Pharma) | $ 0.54 |
| COS-P syr 100ml (Biosync Pharma) | $ 0.54 |
| Cosme | |
| Cosme 100 ml Syrup (Merck (India) Ltd (Merck Ltd)) | $ 0.02 |
| Cosryl (India) | |
| Cosryl Terbutaline 2.5 mg, Guaiphenesin 100 mg, Bromhexine 8 mg, Menthol 5 mg. SYR / 100ml (Cosmas Pharmacls) | |
| Cosryl Terbutaline 2.5 mg, Guaiphenesin 100 mg, Bromhexine 8 mg, Menthol 5 mg. SYR / 60ml (Cosmas Pharmacls) | |
| 100ml (Cosmas Pharmacls) | |
| 60ml (Cosmas Pharmacls) | |
| Cosryl 50 ml Syrup (Cosmas Pharmacls) | $ 0.02 |
| COSRYL syr 100ml (Cosmas Pharmacls) | |
| COSRYL syr 60ml (Cosmas Pharmacls) | |
| Coughtimi (Japan) | |
| Coughxin (Taiwan) | |
| Coughxin 8 mg x 500's | |
| Coughxin 8 mg x 1000's | |
| Covent | |
| Covent 100 ml Syrup (Zaneka Pharmaceuticals (P) Ltd.) | $ 0.02 |
| COVENT 100MG/2.5MG/8MG EXPECTORANT 1 bottle / 100 ML expectorant each (Zaneka Pharmaceuticals (P) Ltd.) | $ 0.46 |
| Covent Expectorant (Zaneka Pharmaceuticals (P) Ltd.) | $ 0.00 |
See 1877 substitutes for Cofrav | |
References
- PubChem. "bromhexine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Bromhexine". http://www.drugbank.ca/drugs/DB09019 (accessed September 17, 2018).
- MeSH. "Expectorants". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Cofrav are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Cofrav. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
